"Antidepressive Agents" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Mood-stimulating drugs used primarily in the treatment of affective disorders and related conditions. Several MONOAMINE OXIDASE INHIBITORS are useful as antidepressants apparently as a long-term consequence of their modulation of catecholamine levels. The tricyclic compounds useful as antidepressive agents (ANTIDEPRESSIVE AGENTS, TRICYCLIC) also appear to act through brain catecholamine systems. A third group (ANTIDEPRESSIVE AGENTS, SECOND-GENERATION) is a diverse group of drugs including some that act specifically on serotonergic systems.
| Descriptor ID |
D000928
|
| MeSH Number(s) |
D27.505.954.427.700.122
|
| Concept/Terms |
Antidepressive Agents- Antidepressive Agents
- Agents, Antidepressive
- Antidepressant Drugs
- Drugs, Antidepressant
- Antidepressants
|
Below are MeSH descriptors whose meaning is more general than "Antidepressive Agents".
Below are MeSH descriptors whose meaning is more specific than "Antidepressive Agents".
This graph shows the total number of publications written about "Antidepressive Agents" by people in this website by year, and whether "Antidepressive Agents" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1997 | 1 | 1 | 2 |
| 1998 | 2 | 0 | 2 |
| 1999 | 1 | 1 | 2 |
| 2000 | 2 | 2 | 4 |
| 2001 | 0 | 1 | 1 |
| 2002 | 1 | 1 | 2 |
| 2003 | 3 | 1 | 4 |
| 2004 | 3 | 1 | 4 |
| 2005 | 2 | 8 | 10 |
| 2006 | 5 | 3 | 8 |
| 2007 | 4 | 2 | 6 |
| 2008 | 6 | 4 | 10 |
| 2009 | 5 | 3 | 8 |
| 2010 | 4 | 4 | 8 |
| 2011 | 8 | 4 | 12 |
| 2012 | 6 | 3 | 9 |
| 2013 | 6 | 3 | 9 |
| 2014 | 4 | 4 | 8 |
| 2015 | 8 | 3 | 11 |
| 2016 | 6 | 1 | 7 |
| 2017 | 10 | 5 | 15 |
| 2018 | 8 | 7 | 15 |
| 2019 | 8 | 4 | 12 |
| 2020 | 4 | 12 | 16 |
| 2021 | 2 | 1 | 3 |
| 2022 | 2 | 16 | 18 |
| 2023 | 4 | 11 | 15 |
| 2024 | 10 | 3 | 13 |
| 2025 | 9 | 2 | 11 |
To return to the timeline,
click here.
Below are the most recent publications written about "Antidepressive Agents" by people in Profiles.
-
Factors associated with initial medication adherence with first-line therapy for depression. J Affect Disord. 2025 Dec 15; 391:120004.
-
Examining Antidepressant Side Effect Burden in Youth: The FIBSER-C Scale in the Texas Youth Depression and Suicide Research Network Study. J Child Adolesc Psychopharmacol. 2025 Oct; 35(8):463-470.
-
Effect of augmentation with aripiprazole or augmentation with repetitive transcranial magnetic stimulation versus switching to the antidepressant venlafaxine extended release/duloxetine on cognition: A comparative effectiveness research trial for antidepressant incomplete and non-responders with treatment-resistant depression (ASCERTAIN-TRD). J Affect Disord. 2025 Dec 01; 390:119836.
-
Psychopharmacological Therapy Positively Modulates Disease Activity in Inflammatory Bowel Disease: A Systematic Review. Int J Mol Sci. 2025 Jul 06; 26(13).
-
Health care resource utilization and costs associated with switching versus augmenting antidepressant monotherapy in second-line treatment of major depressive disorder. J Affect Disord. 2025 Dec 15; 391:119787.
-
Lessons learned from the regulatory alignment in ketamine, esketamine and arketamine clinical trials: A cross-sectional analysis of protocols from ClinicalTrials.gov. Psychiatry Res. 2025 Aug; 350:116559.
-
The effect of adjunctive cariprazine on symptoms of anhedonia in patients with major depressive disorder. J Affect Disord. 2025 Sep 15; 385:119366.
-
Azetukalner, a Novel KV7 Potassium Channel Opener, in Adults With Major Depressive Disorder: A Randomized Clinical Trial. JAMA Netw Open. 2025 05 01; 8(5):e2514278.
-
Lack of relationships between ketamine treatment and peripheral neurotrophic and inflammatory factors in a randomized controlled ketamine trial of major depressive disorder. Brain Behav Immun. 2025 Aug; 128:170-178.
-
Concurrent Depression Management in Patients with Opioid Use Disorder Undergoing Buprenorphine Therapy: Association with Buprenorphine Discontinuation. J Dual Diagn. 2025 Apr; 21(2):142-151.